NewslettersPancreatic Cell NewsActuate Therapeutics Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Pancreatic CancerBy Laurisa Dohm - August 1, 20230164Elraglusib is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta inhibitor which is being developed for adults and children with advanced refractory cancers.[Actuate Therapeutics]Press Release